Prokidney
Salem
About Prokidney
ProKidney offers treatment of chronic kidney disease (CKD) through innovations in cellular therapy. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $345.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: nasdaq:PROK
- Website: prokidney.com
Industries & Categories
Health Care, Therapeutics
Canonical: https://fsome.com/organization/prokidney-23882 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.